Myxofibrosarcoma Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting myxofibrosarcoma clinical trials across 4 countries. Studies span Phase 2, Phase 1. Top locations include Chicago, Illinois, United States, Oslo, Norway, Bergen, Norway. Updated daily from ClinicalTrials.gov.


Myxofibrosarcoma Trials at a Glance

6 actively recruiting trials for myxofibrosarcoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Chicago, Oslo, and Bergen. Lead sponsors running myxofibrosarcoma studies include Oslo University Hospital, Epkin, and Memorial Sloan Kettering Cancer Center.

Browse myxofibrosarcoma trials by phase

Treatments under study

About Myxofibrosarcoma Clinical Trials

Looking for clinical trials for Myxofibrosarcoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myxofibrosarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myxofibrosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

SarcomaNon-small Cell Lung CancerNSCLC+12 more
Epkin146 enrolled10 locationsNCT06789172
Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled7 locationsNCT06239272
Recruiting
Phase 1

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Phase 2

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

SarcomaAlveolar Soft Part SarcomaUndifferentiated Pleomorphic Sarcoma+1 more
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT04332874
Recruiting
Phase 2

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma

Soft Tissue Sarcoma AdultLeiomyosarcomaSynovial Sarcomas+6 more
Oslo University Hospital110 enrolled4 locationsNCT07169344
Recruiting
Phase 2

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Soft Tissue Sarcoma (STS)Soft Tissue Sarcoma AdultSynovial Sarcomas+7 more
Oslo University Hospital40 enrolled2 locationsNCT07173972